MOLECULAR CHARACTERIZATION OF ROCHALIMAEA ANTIGENS

杆状血管瘤病(BA)是一种血管增生性疾病。 皮肤和内脏器官最初被描述为艾滋病毒感染患者。这个 本病的病因有两种，一是高度挑剔，二是 亲缘关系密切的细菌Rochalimaea henselae和R.Quintana。自BA以来 是一种新描述的疾病，而亨塞莱斯是最近描述的一种疾病 生物体，这些重要的、免疫活性的抗原 生物体还没有被定义。拟议中的长期目标 研究目的是鉴定海南红假单胞菌的免疫活性蛋白和 R.Quintana，并表征它们在免疫应答中的作用 罗氏杆菌感染。这些研究旨在产生新的 罗氏原虫的抗原组成和体液的信息 对感染罗氏杆菌的免疫反应。通过分析特定的 在分子水平上，我们应该 能够生产出有价值的诊断罗氏杆菌的试剂 感染。 该项目的具体目标是：1)确定免疫优势抗原 2)编码基因的克隆和测序 这些主要抗原蛋白；3)重组抗原的鉴定 作为BA和猫抓病(CSD)的诊断试剂。最基本的 该方法将用于筛选新疆红曲霉重组基因文库和 昆塔纳红曲霉与人血清反应抗原的表达 BA和GSD患者。免疫反应克隆将被亚克隆，以及 测序，这些重组体将成为单个蛋白质的来源 作为免疫诊断试剂的评估和分析其 在感染罗氏杆菌的免疫反应中的作用。

Bacillary angiomatosis (BA) is a vascular proliferative disease of the skin and visceral organs initially described in HIV-infected patients. The etiologic agents of this disease are two species of highly fastidious, and closely related bacteria, Rochalimaea henselae and R. quintana. Since BA is a newly described disease and R. henselae is a recently described organism, the important, immunologically active antigens of these organisms have not yet been defined. The long range goals of the proposed studies are to identify immunologically active proteins of R. henselae and R. quintana and to characterize their roles in the immune response to Rochalimaea infection. These studies are designed to produce new information about the antigenic composition of Rochalimaea and the humoral immune response to infection with Rochalimaea. By analyzing specific Rochalimaea antigens (and their genes) at the molecular level, we should be able to produce valuable reagents for the diagnosis of Rochalimaea infections. Specific aims of the project are: 1) identify the immuno-dominant antigens of R. henselae and R. quintana; 2) cloning and sequencing the genes coding these major antigenic proteins; and 3) evaluating the recombinant antigens as diagnostic reagents for BA and cat-scratch disease (CSD). The basic approach will be to screen recombinant gene libraries of R. henselae and R. quintana for expression of antigens reactive with human sera from patients with BA and GSD. Immunoreactive clones will be subcloned, and sequenced and these recombinants will be sources of individual proteins for evaluation as immunodiagnostic reagents and studies to analyze their roles in the immune response to infection with Rochalimaea.